FOLDライブシグナル | Getagraph.comで利益を最大化

買う 107765 min ago

@ $13.20

発行日: 15 2月 2024 @ 05:36

リターン: -20.45%

前回のシグナル: 2月 14 - 23:30

前回のシグナル: 売る

リターン: 1.62 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:41):

Stats
本日の出来高	328 433
平均出来高	3.06M
時価総額	3.11B
EPS	$0 ( 2024-02-28 )
次の収益日	( $-0.0600 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-20.59
ATR14	$0.00800 (0.08%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-15	Prout Samantha	Sell	7 027	Common Stock
2024-04-01	Campbell Bradley L	Buy	7 500	Common Stock
2024-04-01	Campbell Bradley L	Sell	7 500	Common Stock
2024-04-01	Campbell Bradley L	Sell	7 500	Stock Options (right to buy)
2024-03-15	Campbell Bradley L	Sell	13 375	Common Stock

INSIDER POWER
17.39
Last 100 transactions
Buy: 1 738 926 \| Sell: 1 191 633

ボリューム相関

長: 0.10 (neutral)

短: 0.62 (weak)

Signal:(74.689) Neutral

Amicus Therapeutics Inc 相関

10 最も正の相関
FULC	0.898
SMSI	0.893
SLS	0.878
PRAX	0.86
GRFS	0.851
CNDT	0.851
NVCR	0.849
LPCN	0.848
SYBX	0.848
ICCC	0.846

10 最も負の相関
TLMD	-0.848
CNCE	-0.828
TYHT	-0.812
OPCH	-0.811
EPZM	-0.809

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Amicus Therapeutics Inc 相関 - 通貨/商品

-0.39
( neutral )

-0.61
( weak negative )

0.00
( neutral )

0.75
( moderate )

0.58
( weak )

Amicus Therapeutics Inc 財務諸表

Annual	2023
収益:	$399.36M
総利益:	$354.16M (88.68 %)
EPS:	$-0.510

FY	2023
収益:	$399.36M
総利益:	$354.16M (88.68 %)
EPS:	$-0.510

FY	2022
収益:	$329.23M
総利益:	$290.63M (88.28 %)
EPS:	$-0.820

FY	2021
収益:	$305.51M
総利益:	$271.05M (88.72 %)
EPS:	$-0.920

Financial Reports:

No articles found.

Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.